BRIEF-Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial Of Ocu400

Reuters

2025/01/13

Jan 13 (Reuters) - Ocugen Inc :

* OCUGEN, INC. ANNOUNCES POSITIVE 2-YEAR DATA ACROSS MULTIPLE MUTATIONS FROM PHASE 1/2 CLINICAL TRIAL OF OCU400 —A NOVEL MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA

* OCU400 SHOWS FAVORABLE LONG-TERM SAFETY AND TOLERABILITY

* PHASE 3 OCU400 TRIAL ON TARGET FOR BLA SUBMISSION IN 2026

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503370287"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503370287\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503370287?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 19:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503370287","market":"us","top_or_hot":-1,"title":"BRIEF-Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial Of Ocu400","media":"Reuters","content":"<html><body><p>Jan 13 (Reuters) - <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> Inc   :</p><p>   * OCUGEN, INC. ANNOUNCES POSITIVE 2-YEAR DATA ACROSS MULTIPLE MUTATIONS FROM PHASE 1/2 CLINICAL TRIAL OF OCU400 —A NOVEL MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA</p><p>   * OCU400 SHOWS FAVORABLE LONG-TERM SAFETY AND TOLERABILITY</p><p>   * PHASE 3 OCU400 TRIAL ON TARGET FOR BLA SUBMISSION IN 2026</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial Of Ocu400</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial Of Ocu400\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-13 19:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 13 (Reuters) - <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> Inc   :</p><p>   * OCUGEN, INC. ANNOUNCES POSITIVE 2-YEAR DATA ACROSS MULTIPLE MUTATIONS FROM PHASE 1/2 CLINICAL TRIAL OF OCU400 —A NOVEL MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA</p><p>   * OCU400 SHOWS FAVORABLE LONG-TERM SAFETY AND TOLERABILITY</p><p>   * PHASE 3 OCU400 TRIAL ON TARGET FOR BLA SUBMISSION IN 2026</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2503370287","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503370287","pubTimestamp":1736769231,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 13  - Ocugen Inc   :   * OCUGEN, INC. ANNOUNCES POSITIVE 2-YEAR DATA ACROSS MULTIPLE MUTATIONS FROM PHASE 1/2 CLINICAL TRIAL OF OCU400 —A NOVEL MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA   * OCU400 SHOWS FAVORABLE LONG-TERM SAFETY AND TOLERABILITY   * PHASE 3 OCU400 TRIAL ON TARGET FOR BLA SUBMISSION IN 2026Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4563":"昨日强势股"},"translate_title":"简介-Ocugen，Inc.宣布OCU400 1/2期临床试验中多个突变的2年积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":1},"content_text":"Jan 13 (Reuters) - Ocugen Inc   :   * OCUGEN, INC. ANNOUNCES POSITIVE 2-YEAR DATA ACROSS MULTIPLE MUTATIONS FROM PHASE 1/2 CLINICAL TRIAL OF OCU400 —A NOVEL MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA   * OCU400 SHOWS FAVORABLE LONG-TERM SAFETY AND TOLERABILITY   * PHASE 3 OCU400 TRIAL ON TARGET FOR BLA SUBMISSION IN 2026Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}